Back to Search
JOHN AMATRUDA, M.D.
M.D.
Specialist
NPI: 1164569224Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Structure-activity relationship studies of small-molecule inhibitors of Wnt response.
PMID 19410457·Bioorg Med Chem Lett·2009
7-preclinical
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.
PMID 19253204·Horm Metab Res·2009
3-trial
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
PMID 19232032·Curr Med Res Opin·2009
4-observational
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
PMID 19125156·Nat Chem Biol·2009
8-other
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
PMID 19097665·Diabetes Res Clin Pract·2009
2-rct
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
PMID 18954434·BMC Endocr Disord·2008
8-other
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
PMID 18518892·Diabetes Obes Metab·2008
4-observational
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3.
PMID 18510930·Cell·2008
7-preclinical
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
PMID 18194595·Curr Med Res Opin·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 15 WEST 81 STEEET, 15J
NEW YORK, NY 10024 - Phone
- (917) 930-4796
Quick Facts
- NPI
- 1164569224
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile